of the publications have IF > 5
of the publications have international collaborators
are results of collaborations within PRIMA
Publications
31 publications were published in peer reviewed international journals, including 3 invited science commentaries in Nature Methods, Nature Immunology, and Cancer Cell.
Impact factor (IF)
Dissemination
Centre researchers have actively contributed to the scientific community, giving 46 invited lectures and 19 poster presentations at national and international conferences and meetings. In total, our projects have been showcased globally 65 times between October 1, 2024 and September 30, 2025.
Publication in the media
Our researchers have contributed to national and international public media 26 times through interviews, blog posts, debates, podcasts, and feature articles during the period from October 1, 2024 and September 30, 2025.
Education
Seven PhD students defended their doctoral thesis in 2025 (3 males, 4 females, listed below)
Dissertations
PhD
Isaac Blaas
CD8 T-cell responses to SARS-CoV-2 in healthy individuals and B-cell depleted lymphoma patients
PhD
Mirjam Podgorica
Precision medicine in B-cell acute lymphoblastic leukemia with subtype classification for biomarker and therapeutic target discovery
PhD
Eivind Heggernes Ask
Integrative immune profiling and computational tools for prognostic biomarker discovery in lymphoma (Photo Jon Olav Nesvold)
PhD
Herman Netskar
Single-Cell Mapping of Natural Killer Cell Diversity
PhD
Aina Anthi
Human albumin with improved FcRn binding as a carrier for therapeutics and subunit vaccines. (Photo Øystein Horgmo)
PhD
Marit Otterlei Fjørtoft
Characterizing the immune microenvironment of primary breast tumors and lymph nodes by mass cytometry
PhD
Katariina Mamia
Precision T cell correction platform for Inborn Errors of Immunity' for the degree of PhD
Total funding
PRIMA is funded by a Centre of Excellence grant from the Research Council of Norway (RCN), own financing from UiO and OUS, and from other external funding bodies.
PRIMA's external funding primarily comes from national sources, including other project funding from the Research Council of Norway, the South-Eastern Norway Regional Health Authority, and the Norwegian Cancer Society.
In 2025, 32% (36.3 M) of PRIMA’s total external funding came from international sources such as NIH, CRUK, EU, and CEPI, as well as from industry collaborations.